Stock market analyst Sudarshan Sukhani has maintained 'buy' rating on Sun Pharmaceuticals Ind Ltd stock to achieve a short term target of Rs 1785.

According to analyst, the investors can buy the stock with stop loss of Rs 1730.

Today, the stock of the company opened at Rs 1759 on the Bombay Stock Exchange (BSE).

Current EPS & P/E ratio stood at 65.23 and 26.71 respectively.

The share price has seen a 52-week high of Rs 1846 and a low of Rs 1159 on BSE.

On July 21, it was an added win for Sun Pharma in its 3-year long fight to adopt Israeli drug company Taro Pharmaceuticals.

Sun Pharma announced that a US court has ignored a court case lodged by Taro to barricade an open offer initiated by the domestic pharma major to get hold of shares of the Tel Aviv-based company.

On July 15, Sun Pharma announced that it got the US health regulator's authorization to sell a generic version of Flomax tamsulosin capsules, which are suggested for the treatment of enlarged prostate, in the US market.

The company has bagged the ANDA nod from the USFDA for tamsulosin hydrochloride capsules in the potencies of 0.4 mg.